财新传媒
财新传媒
1111111
财新通行证
财新英文

Questions Swirl Around China’s New Alzheimer’s Drug

2019年11月07日 21:07
T中
As company revs up for mass production, experts and the drug regulator say more evidence is needed of the effectiveness and safety of Oligomannate

News that China’s medical regulator conditionally approved a novel, locally made drug to treat some symptoms of Alzheimer’s disease raised the hopes of many and prompted plenty of patriotic chest-thumping.

But while the drug’s mechanism sounds promising and reflects current research trends, questions persist over the scant evidence provided for its effectiveness and safety, drawing skepticism from industry insiders and researchers alike.


版面编辑:喻竹杨洋

财新网所刊载内容之知识产权为财新传媒及/或相关权利人专属所有或持有。未经许可,禁止进行转载、摘编、复制及建立镜像等任何使用。

如有意愿转载,请发邮件至hello@caixin.com,获得书面确认及授权后,方可转载。

财新移动
说说你的看法...
分享
取消
发送
注册
 分享成功
相关文章
    大家正在看